Spotlight On... FDA pushes CTI to pull app for myelofibrosis med after trial deaths; Remicade biosim wins big FDA panel backing; Merck files dust mite allergy remedy in U.S.; and more...

The FDA has decided that the adverse events and deaths recorded in CTI BioPharma's pivotal program of the myelofibrosis drug pacritinib are so alarming that they've imposed a full clinical hold on the trial, halting dosing and persuading the biotech to yank its newly completed drug application. CTI is partnered with Baxalta ($BXLT) on the drug, which would compete with Novartis' ($NVS) Jakafi. More from FierceBiotech

> An FDA advisory panel overwhelmingly backed a biosimilar version of Johnson & Johnson's ($JNJ) Remicade, from Celltrion and Pfizer ($PFE), for all of the brand's approved indications. Report

> Merck & Co. ($MRK) filed for FDA approval for its dust mite allergy treatment. Report

> Novartis ($NVS) is taking aim at proposed changes to the U.K. Cancer Drugs Fund, which pays for treatments not cleared as cost-effective by government watchdogs. Report

And Finally... The National Institute for Health and Care Excellence (NICE) in England put out new guidelines for treatment multiple myeloma. Report

Suggested Articles

Just how expensive can pharmacy medicines get? As much as a buying a luxury car every month, according to GoodRx's latest ranking.

Eisai's Belviq has long struggled to prove itself in obesity. With a recall underway after a cancer risk scare, Belviq's chances may be gone for good.

GBT, a pioneer in the sickle cell field with recently approved Oxbryta, sees an example to emulate as it embarks on its first launch: HIV.